Clinical Trial Update: Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) [Phase 1]

View source ↗

Summary

Phase Ib first-in-human dose-escalation study of GT103 in patients with refractory, advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GT103

Snippet

Sponsor: Edward Patz | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED